Drug intelligence / Profile preview

BG-301

Development stage: Preclinical
Lead developer: BlissGene Therapeutics
Modality: Gene Therapies

Overview

BG-301 is an investigational gene therapy being developed by BlissGene Therapeutics for the treatment of major depression. Currently in the discovery stage, the therapeutic is designed to modulate gene expression within the prefrontal cortex and hippocampus, two brain regions that play a central role in mood regulation and the pathophysiology of depressive disorders. By utilizing a gene therapy modality, BG-301 aims to address the underlying molecular mechanisms of depression, potentially offering a novel approach to managing treatment-resistant or severe cases of the disease.

Targets

PABPN1 (Polyadenylate-binding nuclear protein 1)

Beyond the preview

Go deeper on BG-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG-301.